Journal Article

Voriconazole-induced periostitis: beyond post-transplant patients

Reber, Joshua D., McKenzie, Gavin A., Broski, Stephen M.

2016

Overview

Voriconazole-induced periostitis (VIP) is a rare but increasingly encountered entity since Food and Drug Administration (FDA) approval of the second generation antifungal medication in 2002. Literature reports most commonly include transplant recipients on immunosuppressive therapy simultaneously requiring antifungal therapy. Nontransplant patients receiving long-term voriconazole have an equal risk of developing the disease, but may experience a delay in diagnosis due to a lack of familiarity with the process outside of the post-transplant and/or immunosuppressed population. We present a case of VIP in a nontransplant, immunocompetent patient on suppressive antifungal therapy for prior abdominal aortic stent graft fungal infection. Radiologist review of current medications and recognition of periostitis on multiple imaging modalities may hasten the diagnosis and lead to earlier treatment and resolution of symptoms.

• Publisher: Springer Berlin Heidelberg,Springer,Springer Nature B.V
• Subject: Antifungal Agents - adverse effects / Bone diseases / Care and treatment / Case Report / Caspofungin / Diagnosis, Differential / Drug approval / Dysplasia / Health aspects / Humans / Imaging / Immunotherapy / Male / Medicine / Medicine & Public Health / Middle Aged / Mycoses / Nuclear Medicine / Organ transplant recipients / Organ Transplantation / Orthopedics / Pathology / Periosteum - diagnostic imaging / Periosteum - drug effects / Periostitis - chemically induced / Periostitis - diagnostic imaging / Radiology / Voriconazole - adverse effects